Abstract
Introduction: Small molecule tyrosine and serine-threonine kinase inhibitors (TKIs and STKIs) are emerging drugs that interfere with downstream signaling pathways involved in cancer proliferation, invasion, metastasis and angiogenesis. The understanding of their pharmacokinetics, the identification of their transporters and the modulating activity exerted on transporters is pivotal to predict therapy efficacy and to avoid unwarranted drug treatment combinations.
Areas covered: Experimental or in silico data were collected and summarized on TKIs and STKIs physico-chemical properties, which influence their transport, metabolism and efficacy, and TKIs and STKIs as influx transporter substrates and inhibitors. In addition, the uptake by tumor cell influx transporters and some factors in the tumor microenvironment affecting the uptake of TKIs and STKIs by cancer cells are briefly covered.
Expert opinion: Membrane transporters play an important role in the pharmacokinetics and hence the efficacy of anticancer drugs, including TKIs and STKIs. These drugs are substrates and inhibitors of various transporters. Drug resistance may be bypassed not only by identifying the proper transporter but also by selective combinations, which may either downregulate or increase transporter activity. However, care has to be taken because this profile might be disease, drug and patient specific.
Acknowledgments
Conception of idea: CG Da Silva, GJ Peters and RJ Honeywell; CG Da Silva collected initial literature, performed calculations and drafted the first version; RJ Honeywell and H Dekker revised the paper, performed additional calculations and added the additional literature; GJ Peters revised the paper, provided additional literature and made final additions.
Declaration of interest
The authors were supported by VU University Medical Center funds. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Notes
This box summarizes key points contained in the article.
MRoth, AObaidat, BHagenbuch. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 2012;165(5):1260–87 HGlaeser, DGBailey, GKDresser, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007;81:362–70 HKoepsell, KLips, CVolk. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007;24(7):1227–51 ITamai, JNezu, HUchino, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000;273(1):251–60 BMJohnson, WNCharman, CJPorter. The impact of P-glycoprotein efflux on enterocyte residence time and enterocyte-based metabolism of verapamil. J Pharm Pharmacol 2001;53(12):1611–19 Kvan de Wetering, ABurkon, WFeddema, et al. Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol. Mol Pharmacol 2009;75(4):876–85 REvers, GJZaman, Lvan Deemter, et al. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest 1996;97(5):1211–18 AInokuchi, EHinoshita, YIwamoto, et al. Enhanced expression of the human multidrug resistance protein 3 by bile salt in human enterocytes. A transcriptional control of a plausible bile acid transporter. J Biol Chem 2001;276(50):46822–9 Available from: http://www.solvobiotech.com/barriers/intestinal-barrier MRoth, AObaidat, BHagenbuch. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 2012;165(5):1260–87 HGlaeser, DGBailey, GKDresser, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007;81:362–70 HKoepsell, KLips, CVolk. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007;24(7):1227–51 ITamai, JNezu, HUchino, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000;273(1):251–60 BMJohnson, WNCharman, CJPorter. The impact of P-glycoprotein efflux on enterocyte residence time and enterocyte-based metabolism of verapamil. J Pharm Pharmacol 2001;53(12):1611–19 Kvan de Wetering, ABurkon, WFeddema, et al. Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol. Mol Pharmacol 2009;75(4):876–85 RBorchardt, EKerns, MHageman, et al. Optimizing the “drug-like” properties of leads in drug discovery. Springer; New Yprk: 2006 AMCalcagno, JALudwig, JMFostel, et al. Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery. Mol Pharm 2006;3(1):87–93 SZhang, KSLovejoy, JEShima, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 2006;66(17):8847–57 TAbe, MUnno, TOnogawa, et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 2001;120(7):1689–99 WLee, ABelkhiri, ACLockhart, et al. Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res 2008;68(24):10315–23 AMCalcagno, JALudwig, JMFostel, et al. Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery. Mol Pharm 2006;3(1):87–93 MHeise, ALautem, JKnapstein, et al. Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer 2012;12:109 RJHoneywell, SHitzerd, CFatmawati, et al. Uptake and subcellular distribution of tyrosine kinase inhibitors. Manuscript in preparation